Roche Holding AG (RHHVF)
OTCMKTS
· Delayed Price · Currency is USD
323.59
-5.41 (-1.64%)
Jun 27, 2025, 3:31 PM EDT
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B CHF
Revenue Growth
+3.23%
P/S Ratio
3.69
Revenue / Employee
604.32K CHF
Employees
103,249
Market Cap
254.33B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Elite Pharmaceuticals | 70.00M |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Roche Holding AG News
- 4 days ago - Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript - Seeking Alpha
- 4 days ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 7 days ago - Roche's Genentech reports positive results from lymphoma trial - Seeking Alpha
- 7 days ago - Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma - GlobeNewsWire
- 7 days ago - Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma - Business Wire
- 10 days ago - Roche And Prothena: Why Moving On Makes Sense - Seeking Alpha
- 11 days ago - Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue - Seeking Alpha
- 11 days ago - Genentech Provides Update on Phase III Verona Study - Business Wire